प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
रेवोल्यूशन मेडिसिन्स ने daraxonrasib के लिए फेज़ 3 RASolute 302 का टॉपलाइन डेटा जारी किया
The 8-K discloses positive Phase 3 topline results showing daraxonrasib met both PFS and OS endpoints with statistically significant and clinically meaningful benefit versus chemotherapy. The company states these data are now considered final and plans to submit them to global regulators, including the FDA, as part of a future NDA under a Commissioner’s National Priority Voucher.
मुख्य तथ्य
- फाइल किया गया
- 13 अप्रैल 2026, 12:25 pm
- घटना
- टॉपलाइन परिणाम
- दिशा
- सकारात्मक
- संपत्ति
- daraxonrasib
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- रॉयल्टी दर 0 2B
- 4.55%
- रॉयल्टी दर 2 4B
- 2.50%
- रॉयल्टी दर 4 8B
- 1.00%
- अब तक कुल फंडिंग
- $500 मिलियन
- दूसरा ट्रांच फंडिंग
- $250 मिलियन
स्रोत का अंश
8-K false 0001628171 0001628171 2026-04-13 2026-04-13 0001628171 us-gaap:CommonStockMember 2026-04-13 2026-04-13 0001628171 us-gaap:WarrantMember 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 700 Saginaw Drive Redwood City , California 94063 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (650) 481-680
इस संपत्ति पर और
31 अक्टू॰ 2026
12:00 am
RVMDRevolution Medicines13 अक्टू॰ 2026
08:32 pm
RVMDRevolution Medicines